DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.

Yu PeiBue R AgnerBin LuoXiaolin DongDongmei LiJun LiuLei LiuMing LiuYibing LuTomoyuki NishidaXiangjin XuYi-Ming Mu

Published in: Diabetes, obesity & metabolism (2021)

IDegLira may be an efficacious and well-tolerated treatment intensification option for Chinese people with T2D uncontrolled on basal insulin and OADs.

Keyphrases

type diabetes
glycemic control
weight loss
bariatric surgery
body mass index
smoking cessation
combination therapy